Herz · 2004
[Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeymer Uwe, Zahn Ralf, Siegler Karl Ernst, Senges Jochen
Аннотация
BACKGROUND AND PURPOSE: The use of potent platelet inhibitors has been shown to reduce the rate of ischemic complications in patients with percutaneous coronary intervention (PCI) in randomized clinical trials. Eptifibatide is a small-molecule glycoprotein (GP) IIb/IIIa receptor inhibitor. Eptifibatide given with a double bolus of 180 microg/kg 10 min apart followed by an infusion of 2.0 microg/kg/h achieves a high grade of platelet inhibition, which was associated with a highly significant clinical benefit in the randomized ESPRIT Study. The aim of the present prospective registry was to evaluate the efficacy and safety of eptifibatide in clinical practice.
METHODS: A total of 673 patients who received eptifibatide during PCI were prospectively enrolled in the registry between January 2001 and November 2002 in 31 clinical centers.
RESULTS: The intervention was performed for stable angina in 283 patients (42.1%), for unstable angina in 70 patients (10.4%), for non-ST elevation myocardial infarction in 120 patients (17.8%), and for acute ST elevation myocardial infarction in 200 patients (29.7%). Therapy with eptifibatide was predominantly initiated in the catheter laboratory before or during the intervention and maintained for a mean of 20 h. Major bleeding complications, in 50% of the patients at the catheter insertion site, were observed in 1.2% of the patients. A thrombocytopenia < 100,000/microl was not reported. The total mortality rate was < 1%, a myocardial infarction or reinfarction was observed in up to 3%, depending on the clinical indication for PCI.
CONCLUSION: These data are comparable to the results reported in randomized clinical trials with eptifibatide and document the safety and efficacy of this small-molecule GP IIb/IIIa inhibitor in clinical practice in a wide range of patients undergoing PCI.
METHODS: A total of 673 patients who received eptifibatide during PCI were prospectively enrolled in the registry between January 2001 and November 2002 in 31 clinical centers.
RESULTS: The intervention was performed for stable angina in 283 patients (42.1%), for unstable angina in 70 patients (10.4%), for non-ST elevation myocardial infarction in 120 patients (17.8%), and for acute ST elevation myocardial infarction in 200 patients (29.7%). Therapy with eptifibatide was predominantly initiated in the catheter laboratory before or during the intervention and maintained for a mean of 20 h. Major bleeding complications, in 50% of the patients at the catheter insertion site, were observed in 1.2% of the patients. A thrombocytopenia < 100,000/microl was not reported. The total mortality rate was < 1%, a myocardial infarction or reinfarction was observed in up to 3%, depending on the clinical indication for PCI.
CONCLUSION: These data are comparable to the results reported in randomized clinical trials with eptifibatide and document the safety and efficacy of this small-molecule GP IIb/IIIa inhibitor in clinical practice in a wide range of patients undergoing PCI.